New York, NY (PRWEB) March 19, 2014
The prescription drug safety advocates at DrugNews.net are alerting patients taking the blood thinner Pradaxa of new information on the site. Updated court records show the number of lawsuits alleging the drug caused internal bleeding have risen from February to March*.
DrugNews is a free resource providing the latest recalls, safety alerts, research and legal news to those taking popular prescription drugs. Visitors can see if others are experiencing similar side effects, avoid potential dangers and decide if they need legal advice.
Pradaxa was approved by the FDA in 2010 to prevent blood clots and strokes in patients with atrial fibrillation. Experts disagree, however, whether it increases risks of internal bleeding.
DrugNews has included research suggesting patients taking newer blood thinners like dabigatran may be 55% more likely to suffer internal bleeding**. The Institute for Safe Medication Practices has also advised bleeding from Pradaxa could be 5 times as likely to cause death***.
The FDA recently announced it will conduct a new study comparing the safety Pradaxa and the traditional blood thinning medication warfarin****.
Due to the number of families that have filed a Pradaxa lawsuit alleging internal bleeding, cases have been consolidated in a special federal multidistrict litigation court. The case is formally known as MDL No. 2385, IN RE: Pradaxa Product Liability Litigation, Southern District of Illinois.
Now, DrugNews has learned the latest report from the Judicial Panel on Multidistrict Litigation shows the number of lawsuits filed has risen over 4% in less than a month, from 2,139 in February to 2,226 as of March 13th*.
Anyone who suffered internal bleeding after taking Pradaxa is encouraged to visit DrugNews.net or speak with a lawyer about their legal options. DrugNews only recommends lawyers who have already handled Pradaxa lawsuits.
Visit http://www.DrugNews.net today for more information on the research, side effects and litigation news related to Pradaxa and other drugs, or to speak with a lawyer.
*JPML, 3/13/14; jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_District-March-13-2014.pdf
**Gastroenterology, July 2013; gastrojournal.org/article/S0016-5085(13)00290-4/fulltext
***Institute for Safe Medication Practices, 1/9/13; ismp.org/quarterwatch/pdfs/2012Q2.pdf
****Forbes, 1/3/14; forbes.com/sites/larryhusten/2014/01/03/fda-plans-new-safety-assessment-of-dabigatran-pradaxa/